Alzheimer's Patients Being Enrolled in Eli Lilly Study

Eli Lilly has started Phase 3 of a clinical trial investigating the use of a potential new medication for Alzheimer's patients with mild to moderate dementia.  

The medication is a gamma secretase inhibitor, which means it is supposed to inhibit the action of gamma secretase, which is an enzyme that can create amyloid beta, the sticky protein that forms plaque in the brain.  The plaque is believed to be at least partially responsible for killing brain cells, resulting in the cognitive decline that are the hallmark of Alzheimer's dementia.

The clinical trial is called The IDENTITY Trial:  Interrupting Alzheimer's Dementia by EvaluatiNg Treatment of AmyloId PaThologY.

For more information about the IDENTITY Trial, go to Eli Lilly's website:

www.lillytrials.com  or www.clinicaltrials.gov

You can also call 1-877-CTLilly  (1-877-285-4559).